title: [Effects of 2A-1-1 on the aggregation and Ca2+ influx of platelets].
abstract: OBJECTIVE
  To explore the effects of 2A-1-1 (purified component from Panax notoginsengs saponins) on the aggregation of and Ca2+ influx into human platelets.
  
  
  METHODS
  The aggregation of platelets was tested by nephelometry, Fura-2 fluorescent technique was used for detecting cell [Ca2+]i. The effects of 2A-1-1, nifedipine and SK&F96365 on Ca(2+) influx into human platelets induced by ADP or CPA were observed separately.
  
  
  RESULTS
  Nifedipine (< 20 micromol/L) could not inhibit platelet aggregation induced by ADP or the Ca(2+) influx induced by ADP or CPA. SK&F96365 at 20 micromol/L could inhibit the maximal aggregation of platelets induced by ADP with a inhibitory rate of 59.83%, at 15 micromol/L could inhibit the Ca2+ influx induced by CPA or ADP. 2A-1-1 (5, 10 and 20 micromol/L) could inhibit the maximal aggregation of platelets induced by ADP with the inhibitory rates of 47.06%, 53.47% and 71.52%, respectively. 2A-1-1 at 10 and 20 micromol/L could inhibit the Ca2+ influx induced by CPA or ADP.
  
  
  CONCLUSIONS
  2A-1-1 can inhibit platelets aggregation, block the ROC (Receptor-dependent Ca2+ channels) and inhibit Ca2+ influx of human platelets.
authors.affiliation: Department of Hematology, 2nd affiliated hospital of Sun yat-sen University, Guangzhou 510120, China.
authors.forename: Fu-ren
authors.initials: FR
authors.lastname: Zeng
authors.forename: Song-mei
authors.initials: SM
authors.lastname: Yin
authors.forename: Shuang-feng
authors.initials: SF
authors.lastname: Xie
authors.forename: Da-nian
authors.initials: DN
authors.lastname: Nie
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Ma
authors.forename: Jian-hong
authors.initials: JH
authors.lastname: Feng
authors.forename: Li-zhuo
authors.initials: LZ
authors.lastname: Xu
authors.forename: Yong-yuan
authors.initials: YY
authors.lastname: Guan
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism / Q000493:pharmacokinetics*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D036145:Ginsenosides / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D009543:Nifedipine / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*
chemical_list: D002121:Calcium Channel Blockers; D036145:Ginsenosides; D007093:Imidazoles; D007211:Indoles; D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; C063159:1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole; D009543:Nifedipine; D002118:Calcium; C000543:cyclopiazonic acid